Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.

@article{Napoli2007TrimetazidineAR,
  title={Trimetazidine and reduction in mortality and hospitalization in patients with ischemic dilated cardiomyopathy: a post hoc analysis of the Villa Pini d'Abruzzo Trimetazidine Trial.},
  author={Pericle Di Napoli and Paolo Di Giovanni and Marta Assunta Gaeta and Alfonso Antonio Taccardi and Antonio B Barsotti},
  journal={Journal of cardiovascular pharmacology},
  year={2007},
  volume={50 5},
  pages={585-9}
}
The goal of this study was to determine the effects of trimetazidine on all-cause mortality and heart failure hospitalizations in patients with ischemic cardiomyopathy. We performed an extension to 48 months and a post-hoc analysis of the Villa Pini d'Abruzzo trimetazidine trial; in this single-center, open-label, randomized trial with the metabolic inhibitor trimetazidine in chronic heart failure, 61 patients were randomized to either receive trimetazidine (20 mg tid) in addition to their… CONTINUE READING